Tatyana Isayeva*, Margaret Brandwein-Gensler , Maheshika Somarathna , Lakisha D. Moore-Smith and Timmy Lee Pages 4729 - 4744 ( 16 )
Head and neck cancer is one of the leading malignancies worldwide. Due to the lack of symptoms in the early stage of the disease, about two thirds of patients present with locally advanced disease at the time of diagnosis. Even with significantly improved survival rates over the past two decades due to advanced imaging and treatment modalities, locoregional recurrence rates in patients with advanced disease ranges from 16% to 35%. Alternative therapeutic targets are being developed to improve survival outcomes. MicroRNAs (miRNA or miRs) are a family of small non-coding RNA species that have been demonstrated to regulate all cellular, physiological and developmental processes. Recently, there has been an exponential increase in the number of studies suggesting that miRNA is involved in regulating tumor metastasis, chemoresistance, radioresistance and survival outcomes. MiRNA candidates have been identified as potential prognostic biomarkers to diagnose cancer stages and progression, as well as to monitor follow-up treatment. In this review, we will discuss the miRNA profile in each stage of head and neck patients' therapy, with an emphasis on its application to clinical outcome prognosis.
Head and neck cancer, human papilloma virus, saliva, microRNA, dysregulation, resistance, prognostic marker, outcome.
Department of Medicine, the University of Alabama at Birmingham, Birmingham, AL, 35294, Department of Anatomic Pathology, the University at Buffalo the State University of New York, Buffalo, Department of Medicine, the University of Alabama at Birmingham, Birmingham, AL, 35294, Department of Medicine, the University of Alabama at Birmingham, Birmingham, AL, 35294, Department of Medicine, the University of Alabama at Birmingham, Birmingham, AL, 35294